Study guide

7.3 Diagnostic Testing, Staging, and Prognosis

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

7.3 Diagnostic Testing, Staging, and Prognosis

Key Takeaways Explain This Topic AI

New-diagnosis labs include CBC with smear, TLS chemistries (potassium, phosphate, calcium, uric acid, LDH, creatinine), coagulation studies, and type and screen; add viral serologies and AFP, β-hCG, or catecholamines only when the differential needs them.

Marrow, LP with IT chemotherapy, biopsy, and central-line placement require NPO status, sedation airway safety, and protocol platelet and coagulopathy correction before the needle.

Match imaging to compartment: ultrasound for many abdominal masses, CT for lungs, MRI for CNS and many sarcomas, PET when protocols use it, MIBG for neuroblastoma, bone scan for selected bone-seeking disease.

Stage and risk group are disease-specific tools for treatment intensity—ALL CNS 1/2/3, Murphy–St. Jude NHL, INRG neuroblastoma, PRETEXT hepatoblastoma, IRS rhabdomyosarcoma, AJCC/surgical osteosarcoma—not one adult TNM label.

Histology, cytogenetics, and later MRD refine prognosis after therapy has started; waiting for cytogenetics is expected and is not a sign the diagnosis of cancer is wrong.

Last updated: August 2026

Diagnosis on CPHON is a sequence, not a single scan. TCO II.A.4–5 items test whether you can open the right labs, get a child safely through sedation and a needle, pick imaging that matches the compartment, and explain what a stage and a risk group are for—without dumping every cooperative-group table into a family's first hour. Histology, cytogenetics, and measurable residual disease (MRD) then turn a name into a prognosis. Your job includes the sentence families remember: treatment started, and we are still waiting on cytogenetics.

Labs that belong on the new-diagnosis clipboard

Start with a CBC and peripheral smear . Cytopenias, circulating blasts, and schistocytes change urgency. Chemistries for a suspected hematopoietic or bulky embryonal cancer are a TLS panel: potassium, phosphate, calcium, uric acid, LDH, and creatinine . High potassium and phosphate with falling calcium and rising uric acid is lysis, not a dietary oddity. Coagulation studies (PT, PTT, fibrinogen) catch DIC, especially when APL is possible. Type and screen before invasive procedures and before you might need platelets or red cells.

Add viral serologies (for example hepatitis, HIV, CMV, EBV, varicella) as the protocol and transplant path require—results matter before immunosuppression and before live-virus issues. Tumor markers are not universal. Alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-hCG) belong to suspected germ-cell tumor and hepatoblastoma workups. Catecholamine metabolites (homovanillic acid and vanillylmandelic acid) belong to suspected neuroblastoma. Do not send AFP because it is oncology. A 15-year-old with a distal femoral mass needs osteosarcoma staging, not a reflex pregnancy-tumor marker panel unless the differential includes germ-cell disease.

A 4-year-old with fever, pallor, and a high LDH gets the TLS chemistries before the first steroid dose, not after. A teenager with gingival oozing and a possible APL picture gets fibrinogen and products in the room before the diagnostic marrow, not a casual send-whenever laboratory round.

Procedures: NPO, sedation, counts, and coagulopathy

Bone marrow aspirate and biopsy diagnose leukemia and stage some solid tumors (neuroblastoma, Ewing sarcoma on many protocols). Lumbar puncture with IT chemotherapy stages ALL and lymphoma CNS disease and starts sanctuary therapy. Tumor biopsy belongs to the treating surgical or interventional team so the tract sits in a future resection field. Central line placement is both access and a procedure with bleeding risk.

Safety is protocol, not toughness. Keep the child NPO per anesthesia. Review last meal, last breast milk or formula, and last clear. Sedation safety means airway assessment—never casual sedation of a child with a mediastinal mass who cannot lie flat. Correct coagulopathy and raise platelets to the protocol threshold before marrow, LP, or line insertion. A platelet count of 12,000/µL is not a quick-LP situation. Hold anticoagulants as ordered. Verify type and screen and product availability. After LP with IT methotrexate, watch for post-LP headache, but also for the wrong-route disaster: vincristine is never intrathecal . That check is a diagnostic-day nursing behavior, not only a chemotherapy-chapter trivia item.

A 3-year-old booked for diagnostic LP, marrow, and port placement in one anesthesia needs one NPO clock, one airway plan, platelet and coag clearance, and a time-out that names each IT drug. If the PT is still prolonged and fibrinogen is low, the OR wait is a safety action, not a delay of diagnosis for its own sake.

Imaging that matches the compartment

Ultrasound is the first look at an abdominal mass in a preschooler—fast, no ionizing radiation, good for kidney versus adrenal versus liver. CT maps chest nodules (osteosarcoma, Wilms tumor lungs) and some abdominal extent. MRI is the CNS and bone-marrow-extent study; it is also preferred for many pelvic and extremity sarcomas. PET assesses metabolically active disease in selected lymphomas and sarcomas. MIBG (metaiodobenzylguanidine) scan is the neuroblastoma avidity study. Bone scan hunts osteosarcoma skip lesions and clear-cell sarcoma of kidney bone metastases. Do not send every new leukemia to MIBG, and do not skip chest CT in osteosarcoma because the child is breathing fine.

Radiation exposure is not zero in children. That is why ultrasound and MRI are preferred when they answer the question. It is not a reason to skip a needed chest CT for pulmonary metastases. A 3-year-old with a flank mass starts with ultrasound; a 14-year-old with a distal femoral lesion needs dedicated bone MRI plus chest CT, not a babygram.

What stage is for—disease-specific tools, not one adult TNM

Stage (or risk group) is a language for how much disease is where , so teams assign treatment intensity and talk prognosis . Pediatric oncology does not use one adult AJCC sticker for every diagnosis.

ALL CNS-1 / CNS-2 / CNS-3 : CNS-1 is no blasts in CSF. CNS-2 is blasts with CSF WBC under 5/µL. CNS-3 is blasts with CSF WBC 5/µL or higher, or clinical CNS disease (cranial-nerve palsy, hypothalamic mass). CNS status changes IT intensity and sometimes radiation—not a hallway nickname.

Murphy–St. Jude staging for pediatric NHL : extent of nodal and extranodal disease, including whether marrow or CNS is involved. It is why a huge unresectable abdominal Burkitt lymphoma is not stage I because it started in one organ.

INRG for neuroblastoma : image-defined risk factors and metastatic pattern (L1, L2, M, MS) plus age and biology such as MYCN. It is a risk classifier , not adult stage IV.

PRETEXT for hepatoblastoma : how many liver sections are involved before therapy, plus extrahepatic annotations. It answers resectability versus chemotherapy first.

IRS grouping for rhabdomyosarcoma : residual disease after initial surgery (complete resection, microscopic residual, gross residual, metastatic). Biopsy-only versus primary resection changes group.

AJCC / surgical staging for osteosarcoma : local extent plus skip metastases and lungs. Surgery defines margins; chest CT defines the metastatic conversation.

Do not dump the entire tables. Teach that the wrong staging language is a teaching error: calling neuroblastoma T3N1M1 because someone memorized adult lung-cancer TNM does not help a parent. Stage is a treatment-intensity tool, not a room assignment on the unit.

  • System Used for What the nurse is explaining
  • CNS-1 / 2 / 3 ALL (and some lymphomas) Whether blasts are in CSF and how heavy that involvement is
  • Murphy–St. Jude Pediatric NHL Nodal/extranodal extent including marrow and CNS
  • INRG Neuroblastoma Image-defined risk plus metastases and biology
  • PRETEXT Hepatoblastoma Pretreatment liver extent and resectability
  • IRS group Rhabdomyosarcoma Residual tumor after the first operation
  • AJCC / surgical Osteosarcoma Local margins, skip lesions, and lung metastases
  • Histology, cytogenetics, and MRD as prognosis

Histology (favorable versus anaplastic Wilms tumor; embryonal versus alveolar rhabdomyosarcoma; APL versus other AML) still matters. Cytogenetics and molecular results then overlay risk and targeted therapy, as the previous section taught. MRD is the deepest response measure in ALL and is used in other diseases on protocol: flow cytometry or molecular methods detect leftover disease below a morphologic 5% blast threshold. An MRD-negative marrow after induction is a favorable response signal; persistent MRD escalates risk and may add immunotherapy or transplant conversations. MRD does not replace the diagnostic marrow. It is a later checkpoint.

Explaining waiting for cytogenetics

Families hear a diagnosis on day 1 and then live in a gap. The honest script is: morphology and flow tell us this is leukemia, or this is a small-round-blue-cell tumor, so we can start supportive care and protocol induction. FISH may return in a few days; full karyotype and NGS often take longer. Those results may add imatinib for BCR-ABL1, change Burkitt versus lymphoblastic intensity, or move neuroblastoma risk. Waiting is not a sign the team is unsure the child has cancer. It is the difference between starting safely and locking the final roadmap. Write down what is pending. Offer to repeat the explanation. Do not invent a percentage survival from a result that is not back.

A 6-year-old starts ALL induction on Friday. Monday the parent asks why genetics are still open. You show the TLS labs that are already driving hydration, the CNS LP result that already drove IT methotrexate, and the cytogenetic board that will decide whether a TKI is added. That is diagnostic nursing.

Loading diagram... New-diagnosis sequence from labs to risk group